Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Nvsef crawled date : 2022 - 10 - 14 save search
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala® (mepolizumab) Bio-Thera Solutions, Ltd. announced that dosing has begun in a Phase I cli...
Published: 2022-10-14 (Crawled : 13:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.17%
H: 0.8%
C: -0.75%
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -2.63%
H: 2.37%
C: -2.5%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
DVA | $127.82 1.36% 0.0% 490K
|
Health Services
|
| O: 0.65%
H: 1.88%
C: -0.77%
VRNA | $15.82 -1.74% -1.83% 640K
|
Health Technology
|
| O: 0.4%
H: 1.39%
C: -0.3%
UTHR | $237.99 0.45% 0.45% 400K
|
Health Technology
|
| O: 0.24%
H: 1.71%
C: 1.01%
NNVC | $1.1 -6.38% 0.0% 22K
|
Health Technology
|
| O: 2.34%
H: 0.0%
C: 0.0%
bat2606 nucala solutions biosimilar study
Dry Eye Products Market Worth $9.6+ Billion, Globally, by 2028 at 5+% CAGR | The Insight Partners
Published: 2022-10-14 (Crawled : 11:00) - prnewswire.com
PBH | $69.67 1.93% 0.0% 450K
|
Health Technology
|
| O: 0.45%
H: 0.39%
C: -1.63%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.17%
H: 0.8%
C: -0.75%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.22%
H: 1.32%
C: 0.24%
eye market
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala® (mepolizumab)
Published: 2022-10-14 (Crawled : 11:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.17%
H: 0.8%
C: -0.75%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
bat2606 nucala solutions biosimilar study phase 1
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.